Literature DB >> 18495666

Identification and analysis of conserved sequence motifs in cytochrome P450 family 2. Functional and structural role of a motif 187RFDYKD192 in CYP2B enzymes.

Numan Oezguen1, Santosh Kumar, Aditya Hindupur, Werner Braun, B K Muralidhara, James R Halpert.   

Abstract

Using a multiple alignment of 175 cytochrome P450 (CYP) family 2 sequences, 20 conserved sequence motifs (CSMs) were identified with the program PCPMer. Functional importance of the CSM in CYP2B enzymes was assessed from available data on site-directed mutants and genetic variants. These analyses suggested an important role of the CSM 8, which corresponds to(187)RFDYKD(192) in CYP2B4. Further analysis showed that residues 187, 188, 190, and 192 have a very high rank order of conservation compared with 189 and 191. Therefore, eight mutants (R187A, R187K, F188A, D189A, Y190A, K191A, D192A, and a negative control K186A) were made in an N-terminal truncated and modified form of CYP2B4 with an internal mutation, which is termed 2B4dH/H226Y. Function was examined with the substrates 7-methoxy-4-(trifluoromethyl)coumarin (7-MFC), 7-ethoxy-4-(trifluoromethyl)coumarin (7-EFC), 7-benzyloxy-4-(trifluoromethyl)coumarin (7-BFC), and testosterone and with the inhibitors 4-(4-chlorophenyl)imidazole (4-CPI) and bifonazole (BIF). Compared with the template and K186A, the mutants R187A, R187K, F188A, Y190A, and D192A showed > or =2-fold altered substrate specificity, k(cat), K(m), and/or k(cat)/K(m) for 7-MFC and 7-EFC and 3- to 6-fold decreases in differential inhibition (IC(50,BIF)/IC(50,4-CPI)). Subsequently, these mutants displayed 5-12 degrees C decreases in thermal stability (T(m)) and 2-8 degrees C decreases in catalytic tolerance to temperature (T(50)) compared with the template and K186A. Furthermore, when R187A and D192A were introduced in CYP2B1dH, the P450 expression and thermal stability were decreased. In addition, R187A showed increased activity with 7-EFC and decreased IC(50,BIF)/IC(50,4-CPI) compared with 2B1dH. Analysis of long range residue-residue interactions in the CYP2B4 crystal structures indicated strong hydrogen bonds involving Glu(149)-Asn(177)-Arg(187)-Tyr(190) and Asp(192)-Val(194), which were significantly-reduced/abolished by the Arg(187)-->Ala and Asp(192)-->Alasubstitutions, respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18495666      PMCID: PMC2490781          DOI: 10.1074/jbc.M708582200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  Cytochrome P450 flexibility.

Authors:  Thomas L Poulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

3.  Rational engineering of human cytochrome P450 2B6 for enhanced expression and stability: importance of a Leu264->Phe substitution.

Authors:  Santosh Kumar; Yonghong Zhao; Ling Sun; Surendra S Negi; James R Halpert; B K Muralidhara
Journal:  Mol Pharmacol       Date:  2007-08-22       Impact factor: 4.436

4.  Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 A reveals novel features of cytochrome P450.

Authors:  David Leys; Christopher G Mowat; Kirsty J McLean; Alison Richmond; Stephen K Chapman; Malcolm D Walkinshaw; Andrew W Munro
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

5.  Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

Authors:  Julia Kirchheiner; Christian Klein; Ingolf Meineke; Johanna Sasse; Ulrich M Zanger; Thomas E Mürdter; Ivar Roots; Jürgen Brockmöller
Journal:  Pharmacogenetics       Date:  2003-10

6.  Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.

Authors:  Leah M Hesse; Ping He; Soundararajan Krishnaswamy; Qin Hao; Kirk Hogan; Lisa L von Moltke; David J Greenblatt; Michael H Court
Journal:  Pharmacogenetics       Date:  2004-04

7.  An open conformation of mammalian cytochrome P450 2B4 at 1.6-A resolution.

Authors:  Emily E Scott; You Ai He; Michael R Wester; Mark A White; Christopher C Chin; James R Halpert; Eric F Johnson; C David Stout
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-16       Impact factor: 11.205

8.  Identifying property based sequence motifs in protein families and superfamilies: application to DNase-1 related endonucleases.

Authors:  Venkatarajan S Mathura; Catherine H Schein; Werner Braun
Journal:  Bioinformatics       Date:  2003-07-22       Impact factor: 6.937

9.  Selection of human cytochrome P450 1A2 mutants with enhanced catalytic activity for heterocyclic amine N-hydroxylation.

Authors:  Donghak Kim; F Peter Guengerich
Journal:  Biochemistry       Date:  2004-02-03       Impact factor: 3.162

10.  Total sequence decomposition distinguishes functional modules, "molegos" in apurinic/apyrimidinic endonucleases.

Authors:  Catherine H Schein; Numan Ozgün; Tadahide Izumi; Werner Braun
Journal:  BMC Bioinformatics       Date:  2002-11-25       Impact factor: 3.169

View more
  8 in total

1.  Engineering proteins with enhanced mechanical stability by force-specific sequence motifs.

Authors:  Wenzhe Lu; Surendra S Negi; Andres F Oberhauser; Werner Braun
Journal:  Proteins       Date:  2012-02-10

Review 2.  Substrate tunnels in enzymes: structure-function relationships and computational methodology.

Authors:  Laura J Kingsley; Markus A Lill
Journal:  Proteins       Date:  2015-02-28

3.  Potent mechanism-based inactivation of cytochrome P450 2B4 by 9-ethynylphenanthrene: implications for allosteric modulation of cytochrome P450 catalysis.

Authors:  Haoming Zhang; Sean C Gay; Manish Shah; Maryam Foroozesh; Jiawang Liu; Yoichi Osawa; Qinghai Zhang; C David Stout; James R Halpert; Paul F Hollenberg
Journal:  Biochemistry       Date:  2013-01-04       Impact factor: 3.162

4.  Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.

Authors:  Jyothi C Talakad; Santosh Kumar; James R Halpert
Journal:  Drug Metab Dispos       Date:  2008-12-12       Impact factor: 3.922

5.  Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection.

Authors:  Santosh Kumar; Huan Qiu; Numan Oezguen; Holger Herlyn; James R Halpert; Leszek Wojnowski
Journal:  Drug Metab Dispos       Date:  2009-03-19       Impact factor: 3.922

6.  Interactions between CYP2E1 and CYP2B4: effects on affinity for NADPH-cytochrome P450 reductase and substrate metabolism.

Authors:  Cesar Kenaan; Erin V Shea; Hsia-lien Lin; Haoming Zhang; Matthew J Pratt-Hyatt; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-10-05       Impact factor: 3.922

Review 7.  Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation.

Authors:  Santosh Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-02       Impact factor: 4.481

8.  Analysis of Cytochrome P450 Conserved Sequence Motifs between Helices E and H: Prediction of Critical Motifs and Residues in Enzyme Functions.

Authors:  Numan Oezguen; Santosh Kumar
Journal:  J Drug Metab Toxicol       Date:  2011-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.